Incyte Corporation (INCY) News Headlines

▮ More

Date

Headline

6/29/2020 7:28:58 AM Incyte Receives Approval For Tabrecta In Japan For Patients With Advanced NSCLC With METex14

6/29/2020 7:14:24 AM Incyte Announces Approval Of Tabrecta In Japan For Patients With Advanced NSCLC With METex14

6/15/2020 7:00:05 AM Lilly Starts Phase 3 Clinical Trial With Baricitinib For Hospitalized COVID-19 Patients

6/9/2020 7:00:19 AM Incyte To Present At Goldman Sachs Global Healthcare Conference; Webcast At 8:00 AM ET

5/20/2020 9:20:25 PM MorphoSys Announce Validation Of EMA Application For Tafasitamab

5/19/2020 2:05:02 PM Incyte To Present At RBC Capital Healthcare Conference; Webcast At 3:05 PM ET

5/14/2020 9:47:38 AM MorphoSys : Long-term Data From L-MIND Study Confirms Primary Analysis Results

5/14/2020 9:34:56 AM MorphoSys, Incyte Report Updated Results From Ongoing Phase 2 L-MIND Study

5/5/2020 7:49:57 AM Incyte Slips To Loss In Q1, Despite Higher Revenues - Quick Facts

5/5/2020 7:23:21 AM Incyte Q1 Loss Per Share $3.33 Vs EPS $0.47 Last Year

5/5/2020 7:01:41 AM Incyte Q1 20 Earnings Conference Call At 8:00 AM ET

4/20/2020 9:14:03 AM FDA Approves First Targeted Treatment For Bile Duct Cancer

3/16/2020 6:46:54 AM Lilly And Incyte: FDA Grants Breakthrough Therapy Designation To Baricitinib

3/3/2020 9:03:44 PM MorphoSys, Incyte Receive Antitrust Clearance For Collaboration On Tafasitamab

3/2/2020 10:20:12 AM Incyte To Present At Cowen And Co Conference; Webcast At 11:20 AM ET

2/13/2020 7:31:30 AM Incyte Q4 Adj. Operating Income Rises; Jakafi Revenues Up 23% - Quick Facts

2/13/2020 7:24:59 AM Incyte Corporation Q4 adjusted earnings of $0.65 per share

2/13/2020 7:09:06 AM Incyte Q4 GAAP EPS $0.51; Non-GAAP EPS $0.65

2/13/2020 7:02:48 AM Incyte Q4 19 Earnings Conference Call At 8:00 AM ET

2/11/2020 9:42:23 PM Lilly's Study Meets Primary Endpoint Of 75% Improvement Of Skin Inflammation